Drug Trial News

RSS

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis.

23 Apr 2015

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

22 Apr 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).

From Baxter International Inc. 22 Apr 2015

Researchers report advancement in development of Ebola vaccine trials

As the current Ebola outbreak wanes, scientists have to make the most of every opportunity to prepare for future outbreaks. One such opportunity involves the identification of a safe and effective Ebola vaccine. Texas supercomputers have aided researchers in modelling which types of clinical trials will provide the best information. That's according to University of Texas at Austin researchers Steve Bellan and Lauren Meyers, who are studying Ebola vaccine trials with the U.S. Centers for Disease Control and Prevention.

22 Apr 2015

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday).

22 Apr 2015

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific sequences.

From EKF Diagnostics 21 Apr 2015

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma Ltd, the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications.

21 Apr 2015

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.

21 Apr 2015

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.

21 Apr 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates.

20 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

20 Apr 2015

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.

16 Apr 2015

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company's ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver, or the 50th International Liver Congress 2015, taking place in Vienna April 22-26.

16 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

Drug Trial News

Civacir can effectively prevent HCV recurrence following liver transplants

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Researchers report advancement in development of Ebola vaccine trials

Men with prostate cancer benefit from BRCA-targeting drug

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

New drug combination shows promise in patients with metastatic melanoma

Some lung cancer patients can benefit from melanoma drugs

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News